Cathie Wood’s ARK Buys $24M in Figma Stock and Dumps DraftKings in Latest Trades
TLDR
- ARK Invest bought ~$24M in Figma (FIG) after strong Q4 earnings and a 6.9% share price surge
- ARK sold ~$10.8M of DraftKings (DKNG), continuing a steady exit from the gaming platform
- Compass Pathways (CMPS) was bought for ~$6.5M, taking advantage of a dip after a share offering
- Recursion Pharmaceuticals (RXRX) was purchased for ~$2.9M despite Nvidia fully exiting its position
- Pinterest (PINS) was sold for ~$2.66M following weak Q4 2025 results and a poor outlook
Cathie Wood’s ARK Invest made a series of trades on Thursday, February 19, 2026, as revealed in the firm’s daily fund disclosures.
The biggest buy was Figma, the cloud-based design platform that recently went public. ARK purchased 964,342 shares worth roughly $24 million, mostly through its flagship ARKK ETF.
Figma’s stock rose 6.9% on the day. The company had just reported Q4 results that beat both sales and earnings estimates.
Figma, Inc., FIG
Figma CEO Dylan Field also pushed back against fears that AI tools would hurt traditional software companies. He said Figma is using AI to grow, not just survive it.
Figma’s “Make” tool lets users type prompts that AI models from Anthropic and Google turn into app prototypes. Starting in March, the company will charge for AI usage through monthly credit limits and pay-per-use pricing.
ARK Cuts DraftKings and Pinterest
On the sell side, ARK offloaded 480,919 shares of DraftKings for about $10.8 million through its ARKK ETF. This was the second day in a row ARK sold DraftKings stock.
ARK also sold 158,945 shares of Pinterest for $2.66 million. Pinterest recently reported weak Q4 2025 results and issued a soft outlook for the coming quarter.
Mental Health and Biotech Bets
ARK’s genomics-focused ARKG ETF bought 781,085 shares of Compass Pathways for around $6.5 million. The British mental health drug maker’s stock had dipped 2.3% after announcing a 17.5 million share secondary offering priced at $8 per share.
ARK also added 780,532 shares of Recursion Pharmaceuticals for about $2.9 million. Recursion’s stock had jumped 5.4% that day, recovering from a drop caused by news that Nvidia had fully exited its position in the AI drug company during Q4.
ARK also bought 28,055 shares of CRISPR Therapeutics for $1.5 million and 56,507 shares of fintech firm Klarna for just over $1 million.
The firm sold 34,993 shares of Veeva Systems for $6.3 million and 31,523 shares of Twist Bioscience for $1.7 million.
Figma’s stock closed up 6.9% on the day of ARK’s purchase, the strongest single-day move among all stocks involved in Thursday’s trades.
The post Cathie Wood’s ARK Buys $24M in Figma Stock and Dumps DraftKings in Latest Trades appeared first on CoinCentral.
You May Also Like
Exploring Market Buzz: Unique Opportunities in Cryptocurrencies
Tests 50-day EMA barrier near 183.00
